Clinical-stage medical device company PQ Bypass Inc revealed on Monday that it has initiated its TORUS 2 multi-centre clinical trial with the enrollment of the first patient.
PQ Bypass stated it has carried out the inaugural enrolment less than a month after the study received unconditional approval from the FDA for the TORUS 2 original IDE. Vaqar Ali MD, FACC, FSCAI, vice president and Cath Lab Director at First Coast Cardiovascular Institute in Jacksonville, Fla, enrolled and treated the first patient in the trial.
TORUS 2 is a trial of the company's self-expanding TORUS stent graft system, a novel technology designed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). The objective of the trial is to evaluate the safety and effectiveness of the TORUS Stent Graft System in the treatment of obstructive atherosclerotic lesions of the superficial femoral and/or proximal popliteal arteries.
Led by national co-principal investigators Peter Schneider MD, Professor of Surgery, Division of Vascular and Endovascular Surgery at University of California San Francisco, and Ehrin Armstrong MD, MSc, FSCAI, Director of Interventional Cardiology at the Rocky Mountain Regional VA Hospital and Professor of Cardiology at University of Colorado School of Medicine, the PQ Bypass pivOtal IDE intra-aRterial stent graft study for occlUsive and re-Stenotic fem-pop revascularization is a prospective, single-arm trial of 188 patients at up to 40 sites.
The TORUS Stent Graft System received CE Mark in 2017 for use in the DETOUR percutaneous femoropopliteal bypass procedure, based on the DETOUR 1 global study. The technology has also been evaluated in the TORUS 1 study in Europe and is currently under evaluation in the DETOUR 2 IDE for percutaneous femoropopliteal bypass in the US and Europe.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial